“ptc-therapeutics” Archives

in
Entry Author Date Location
Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More 05/08/20 National
PTC Therapeutics to Acquire Censa Pharma for Mid-Stage Rare Disease Drug 05/07/20 New York
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs 05/04/20 Boston
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More 04/24/20 National
Roche Challenger to Biogen’s SMA Drug Succeeds in Pivotal Study 11/11/19 National
FDA Rejects Sarepta’s Second Duchenne Drug, Citing Safety Concerns 08/19/19 Boston
SMA, Migraine Data Lead Neuro Highlights from AAN Meeting 05/07/19 National
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
PTC Dives Into Gene Therapy with $50M Agilis Biotherapeutics Deal 07/19/18 New York
Bio Roundup: Meldonium Slip, Kratom Crackdown, Zinc Fingers & More 02/23/18 National
Solid Discloses Duchenne Problems in IPO & Raises Rival’s Hackles 01/25/18 Boston
Disney, Family Offices Back Second Bio Startup from Tech Entrepreneur Haney 01/23/18 Boston
With $40M for Exonics, Duchenne’s Gene Therapy, CRISPR Race Heats Up 11/08/17 Boston
Bio Roundup: CBO’s Praise, Celgene’s Shock, Trump’s Opioid Plan & More 10/27/17 National
No Charm: PTC’s Duchenne Drug Rejected by FDA for Third Time 10/25/17 New York
Bio Roundup: Graham-Cassidy, Axovant Fail, SpringWorks Launches & More 09/29/17 National
FDA Panel Pans PTC’s Audacious Plan to Force Vote on Duchenne Drug 09/28/17 New York
Bio Roundup: Drug Price Debates, NY Bio Blooms & CEOs Take Social Stand 08/25/17 National
Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More 06/09/17 National
Bio Roundup: Big Apple Mo’, Checkpoint Yes and No, CAR-T Death & More 05/12/17 National
Analysts Expect Payer Pushback as PTC Sets $35K Price For Duchenne Drug 05/08/17 New York
Next Stop on Father’s Duchenne Quest: Wall Street? Solid Raises $50M 03/30/17 Boston
Bio Roundup: Trumpcare Wavers, Amgen Courts Payers, Critics Circle PTC 03/24/17 National
Sanders, Cummings to PTC: Price Duchenne Steroid at Import Cost 03/22/17 New York
After a Clinical Trial Death, FDA OKs New Tests of Akashi’s Duchenne Drug 03/22/17 Boston
Bio Roundup: Trump Budget, FDA Chief, CAR-T Qs, CRISPR Cash, & More 03/17/17 National
For $140M, PTC Gets Duchenne Drug and a Pricing Controversy from Marathon 03/16/17 New York
Biotech Roundup: Obamacare Lite, DePinho Out, Dunsire In & More 03/10/17 National
Bio Roundup: Jenkins Gets Mad, Bernie Gets His Pen, CRISPR IPO & J-Lo 10/21/16 National
Sarepta Preps For Sales As Insurers Unlikely To Deny Duchenne Drug 09/22/16 Boston
Page 1 of 3 next page »